Federica Tomao is an Associate Professor at the Department of Maternal, Child and Urological Sciences within Sapienza University of Rome. She actively teaches and supervises courses in Medicine and Surgery , Nursing , and Midwifery programs across multiple institutions. Current faculty member with academic rank Teaching roles in 6th, 3rd, and 2nd year courses Specialized in gynecologic oncology Research Focus : Her work spans ovarian cancer, breast cancer, and endometrial cancer, emphasizing chemotherapy optimization, precision medicine, and radiomics. Notably, she contributes to understanding PARP inhibitors, immune checkpoint therapies, and fertility preservation techniques in cancer survivors. Recent Publications highlight advancements in sarcopenia analysis, BRCA testing, and radiogenomic nomograms. These studies demonstrate her commitment to bridging imaging and molecular data for improved cancer management. Email : federica.tomao@uniroma1.it
Jillian Bohlen is an Associate Professor at the University of Georgia within the College of Agricultural & Environmental Sciences , specifically the Department of Animal and Dairy Science . Her work focuses on dairy cattle reproduction, teaching, and youth development in agricultural sciences. Education: B.S. in Dairy Science, University of Georgia (2003) M.S. in Dairy Science, University of Georgia (2005) Ph.D. in Animal Sciences, Clemson University (2012) Dr. Bohlen's research emphasizes applied reproduction in cattle , including synchronization techniques, ultrasound applications in reproductive programs, and embryo competency. She integrates students into all research projects despite lacking a formal research appointment. Her teaching interests span dairy cattle production , reproductive management , and contemporary agricultural issues , with courses like ADSC 3620 (Dairy Cattle Production), ADSC 4010 (Issues in Animal Agriculture), and ADSC 4410 (Applied Reproductive Management). Scientific awards include: Student Career Success Influencer Award (2024) Russell Award for Excellence in Undergraduate Teaching (2023) UGA Creative Teaching Award (2022) CAES Early Career Teaching Award (2022) Hoard's Dairyman Youth Development Award (2021) Larry Benyshek Teaching Award (2017) She actively promotes agricultural education through programs like the Commercial Heifer Project , Dairy Cattle Judging , and Dairy Quiz Bowl . Additionally, she participates in funded projects related to methane emissions , heat stress mitigation , and antibiotic alternatives in dairy farming.
Youngjae You is a Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy. His research focuses on Antibody-Drug Conjugates, Cancer Chemotherapy, Medicinal Chemistry, and Targeted Drug Delivery. He holds adjunct roles at the University of Oklahoma Health Sciences Center and has led numerous grants totaling over $10 million in funding. Key awards include the 2019 Professor of Empire Innovation title and multiple DoD/CDMRP grants. His work emphasizes prodrug design, photodynamic therapy, and combination therapies. Education : PhD in Pharmaceutical Chemistry, Chungnam National University (2001) MS in Pharmaceutical Chemistry, Chungnam National University (2000) BPharm, Chungnam National University (1994) Research Interests : Dr. You specializes in developing light-activatable prodrugs for targeted cancer therapies, including far-red/NIR light-activated delivery systems. His work integrates quantitative pharmacokinetic modeling, singlet oxygen dynamics, and receptor-targeted drug conjugation to enhance therapeutic efficacy while minimizing off-target effects. Key applications include bladder, breast, and ovarian cancers. Funding Highlights : NIH/NIGMS: $1.37M (2023-2027) for light-responsive drug delivery National Cancer Institute: $2.1M (2022-2027) for bladder cancer treatments DoD/CDMRP/PRCRP: $392K (2017-2020) for photodynamic-chemotherapy combinations Awards : PHF Presidential Professorship (2018) American Cancer Society Research Scholar Grant (2013) Multiple DoD/CDMRP Idea Awards Service & Grants : Serves as Principal Investigator on 8 major grants. Active reviewer for Wellcome Trust, NIH, and international funding agencies. Holds patents on BODIPY derivatives and singlet oxygen-labile linkers. Lab & Collaborations : Leads the You Lab at UB, collaborating with bioengineers and clinicians to advance photomedicine and targeted drug delivery systems. Engaged in multidisciplinary teams addressing spatiotemporal control in cancer treatments.
Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Lindsey Draper, MD serves as an Adjunct Instructor in the Roybal Laboratory within the Department of Medicine, Division of Hematology and Oncology at the University of California San Francisco School of Medicine. Her clinical practice focuses on the treatment of patients with recurrent ovarian cancer using systemic therapies including chemotherapy and immunotherapy, with a commitment to evaluating and offering clinical trial opportunities as part of individualized patient care. Dr. Draper completed her educational training with a B.S. in Biology from Juniata College (2010), an M.D. from the University of Maryland School of Medicine (2017), an Internal Medicine Residency at The Mount Sinai Hospital (2022), and is currently completing a Medical Oncology Fellowship at UCSF (2025-2027). Her research interests center on cancer immunotherapy, particularly T cell-based approaches for HPV-associated cancers and ovarian cancer. She investigates engineered T cell therapies targeting viral antigens in cervical and other HPV-related cancers, with a focus on overcoming treatment resistance and improving clinical outcomes through novel immunotherapeutic strategies. Her work bridges fundamental immunological mechanisms with clinical applications, emphasizing the translation of laboratory discoveries into patient treatments. Dr. Draper's publication record demonstrates consistent contributions to the field of cancer immunotherapy, with recent work focusing on TCR-engineered T cells for leukemia and HPV-associated malignancies. Her research trajectory shows increasing sophistication in T cell engineering approaches and a growing emphasis on addressing inflammatory responses and treatment resistance mechanisms. Parker Institute for Cancer Immunotherapy Early Career Research Award: Parker Scholar (2024) Gladstone-UCSF Institute of Genomic Immunology Symbiont Seed Grant for 'Antigen Discovery for Ovarian Cancer' (2024) Conquer Cancer Young Investigator Award, American Society of Clinical Oncology (2024) Women in Cancer Immunotherapy Network Leadership Institute Selected Participant, Society for Immunotherapy of Cancer (2024) Physician-Scientist Fellow, Chan Zuckerberg Biohub - San Francisco (2023-2025) As a physician-scientist, Dr. Draper maintains an active research program while providing clinical care, with particular emphasis on developing novel immunotherapies for gynecologic cancers. Her current fellowship at UCSF and multiple early-career awards indicate strong potential for continued contributions to the field of cancer immunotherapy. Dr. Draper works within the Roybal Laboratory at UCSF, which focuses on innovative approaches to cancer immunotherapy and T cell engineering. Her research intersects with multiple collaborative initiatives at UCSF, including the Parker Institute for Cancer Immunotherapy and the Gladstone-UCSF Institute of Genomic Immunology.
Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.
About Dr. Pegah Varamini Dr. Pegah Varamini is a Senior Lecturer in Pharmacy and Pharmacology at the Sydney Pharmacy School, University of Sydney, and a Casual Lecturer in Music Education at the Sydney Conservatorium of Music. She leads the Breast Cancer Targeting & Drug Delivery (BCTDD) Group, focusing on innovative drug delivery systems for Triple Negative Breast Cancer (TNBC). Her research integrates nanotechnology, targeted therapy, and translational medicine, supported by prestigious grants including the NBCF Fellowship (2016). Research & Education PharmD (Shiraz University of Medical Sciences) PhD in Pharmaceutical Sciences (University of Queensland) Second PhD in Music Education (University of Sydney Conservatorium of Music) Key Research Interests Her work centers on: Peptide-based targeting strategies using 'Trojan Horse' approaches for TNBC Development of nanomedicine for bone metastasis prevention Clinically relevant preclinical models for personalized breast cancer treatment Collaborations with international institutions (e.g., Harvard Medical School, University of Nantes) Teaching & Supervision Dr. Varamini coordinates Drug Design and Development (PCOL3012/3912) and supervises a multidisciplinary team of HDR students and postdoctoral researchers. Notable current students include PhD candidate Hany Ghaly and MPhil candidates Huimin Shao and Farhana Mollah. Awards & Recognition 2021 Equity Prize 2016 Top 25 Young Researchers of Australia and New Zealand 2018 Fresh Scientist of the Year Recipient of multiple grants totaling over AUD 2M Leadership & Outreach She co-chairs the Nanopharma cluster at Sydney Nano Institute and advises the WHO Global Breast Cancer Initiative. Her work has been featured in media outlets such as SBS Farsi News and NBCF publications.
Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models
Dr. Karen Anderson is a Professor at Arizona State University (ASU), affiliated with the School of Life Sciences, the Biodesign Center for Personalized Diagnostics, and the College of Health Solutions. Her research focuses on tumor biology and immune system interactions in cancer, particularly developing biomarkers for early detection of cancers like breast, ovarian, pancreatic, and HPV-related cancers. She employs molecular techniques such as protein arrays, next-gen sequencing, and functional genomics to identify therapeutic targets and vaccine candidates. Education: Ph.D. in Microbiology and Immunology (Duke University), M.D. from Duke University School of Medicine, and B.A. in Chemistry (University of Virginia). Research interests include cancer immunotherapy, autoantibody profiling, and translational applications of proteomics. Key achievements include pioneering autoantibody-based biomarker assays and investigating HPV serology in head and neck cancers. Awards include the Health Care Heroes Award and recognition as one of Arizona's Most Influential Women. Teaching responsibilities include courses on research techniques and honors thesis supervision. Grants span biomarker validation, cancer genomics, and point-of-care diagnostics. Active in professional service, including roles in grant review panels and public health initiatives.
Hsueh-Chia Chang is the Bayer Professor of Chemical Engineering in the Department of Chemical and Biomolecular Engineering at the University of Notre Dame's College of Engineering. He also holds a concurrent faculty position in the Department of Aerospace and Mechanical Engineering. As Principal Investigator of the Chang Lab, he leads cutting-edge research in microfluidic and nanofluidic technologies for biomedical applications. Prof. Chang received his B.S. in Chemical Engineering from Caltech in 1976, followed by M.S. and Ph.D. degrees in Chemical Engineering from Princeton University in 1977 and 1980, respectively. His academic journey has established him as a leader in the field of microfluidics and biosensing technologies. Chang's research focuses on developing low-cost liquid biopsy nanotechnologies for cancer screening and therapy management. His lab specializes in microfluidic and nanofluidic research coupled with electrokinetics, optics, plasmonics and acoustics for biosensing applications. Key research areas include Electrokinetics & Biosensing, Optics & Plasmonics, Nanoelectrokinetics, and Droplet Microfluidics. The Chang Lab has developed innovative platforms that can isolate and sort tumor cells, exosomes, microvesicles, lipoproteins, and stress granules from blood samples, then lyse these structures to release RNA/protein biomarkers for detection and quantification. His recent publications reveal a strong focus on extracellular vesicle diagnostics, cancer biomarker detection, and point-of-care diagnostic technologies. The research spans multiple disciplines including oncology, cardiology, and neurology, with applications for pancreatic, liver, breast, ovarian, and lung cancers as well as myocardial infarction diagnosis. Fellow of American Institute of Medical and Biological Engineering (2025) Provost Research Achievement Award, Notre Dame (2024) Fellow of the National Academy of Inventors (2020) Lifetime Achievement Award, American Electrophoresis Society (2019) Fellow of the American Physical Society (1997) Presidential Young Investigator Award, NSF (1985) Prof. Chang has advised over 50 PhD students and postdocs who have gone on to prominent positions in academia and industry. His lab has secured significant funding and has commercialized several technologies through startups like Aopia Biosciences, which launched NanoEx at ISEV 2024. The Chang Lab maintains active collaborations with medical researchers for validating their diagnostic platforms against various cancers and cardiac conditions.
Vikas Singh is a Professor in the Department of Biostatistics at the University of Wisconsin-Madison, with appointments in Computer Sciences and Statistics. He also serves as a part-time Faculty Researcher at Google DeepMind. His research focuses on image analysis, machine learning, and medical imaging applications, particularly in neuroimaging and Alzheimer's disease studies. Singh holds a Ph.D. in Computer Science from SUNY Buffalo and has taught courses such as BMI/CS 767 (Medical Image Analysis) and CS 766 (Computer Vision). Affiliations: UW Computer Vision Group, Wisconsin Alzheimer's Disease Research Center (W-ADRC), Machine Learning@UW. Research: Develops algorithms for medical image analysis, including tools for neuroimaging and longitudinal biomarker studies. Grants: Collaborates on grants related to Alzheimer's progression modeling and imaging techniques. His work emphasizes interdisciplinary applications, bridging statistics, geometry, and optimization to solve real-world problems in healthcare and engineering.
Cathy Wu is a distinguished academic holding the Unidel Edward G. Jefferson Chair in Engineering and Computer Science at the University of Delaware. She serves as Director of the Center for Bioinformatics & Computational Biology (CBCB), Data Science Institute (DSI), and Protein Information Resource (PIR). Her roles include professorships in the Departments of Computer & Information Sciences and Biological Sciences. Education: BS in Plant Pathology (National Taiwan University, 1978), MS and PhD in Plant Pathology (Purdue University, 1982–1984), and a second MS in Computer Science (University of Texas at Tyler, 1989). She completed postdoctoral training in Molecular Biology at Michigan State University (1985–1986). Research interests focus on computational biology, bioinformatics, and data science with emphasis on protein informatics, biological text mining, ontology development, gene-disease-drug networks, and machine learning applications. She leads initiatives in integrating FAIR principles into biological databases like UniProt and InterPro. Her work bridges computational methods with biomedical challenges, including cancer genomics, epigenetic regulation, and proteomic analyses. She has spearheaded educational programs such as the Online Graduate Certificates in Applied Bioinformatics and Biomedical Informatics and Data Science. Her contributions include over 290 peer-reviewed publications (48,000+ citations, h-index 71) and authored/co-authored four books on bioinformatics. She directs multidisciplinary research teams and collaborates internationally on projects like the HALO study on ovarian cancer genetics. Awards and recognition are implied through her leadership roles and academic appointments, though specific prizes are not listed here. Her grants and funding support large-scale initiatives in bioinformatics infrastructure and translational research.
Pengyu Chen is Francis Family Associate Professor and Ginn Faculty Achievement Fellow in Materials Engineering at Auburn University. His NIH-funded research develops nanoplasmonic biosensors for rapid disease diagnosis and immune monitoring, with applications in precision medicine and cancer immunotherapy. Research focuses on: Rapid diagnostic technologies for COVID-19 and other diseases Single-cell analysis platforms Nanoparticle-based cancer therapies Food/environmental safety monitoring Recent publications demonstrate innovations in nanoplasmonic sensing, targeted drug delivery, 3D-printed implants, and tumor microenvironment analysis. His work integrates nanotechnology, immunology, and microfluidics for biomedical applications.
Ben Cosgrove is an Associate Professor in the Meinig School of Biomedical Engineering at Cornell University, serving as Director of Graduate Studies. His research focuses on systems bioengineering approaches to understand muscle stem cell dysfunction in aging and disease. He leads the Cosgrove Lab, a multidisciplinary group integrating biomedical engineering, stem cell biology, and systems biology to study microenvironmental signaling in muscle regeneration. His work includes developing biomimetic microenvironments for stem cell manufacturing and improving regenerative medicine therapies. Dr. Cosgrove holds a B.Eng. from the University of Minnesota (2003) and a Ph.D. in Bioengineering from MIT (2009). Postdoctoral training at Stanford University (with Dr. Helen Blau) followed. His research is supported by NIH grants (including R01, R21), the Glenn Medical Research Foundation, and others. He has been recognized with awards such as the BMES Graduate Research Award (2008), Rising Star Award (2015), and Swanson Teaching Excellence Award (2019). Research interests span bioengineering, biomechanics, computational science, and systems biology. His lab's innovations include spatial transcriptomic mapping and high-yield stem cell expansion platforms. Current projects aim to decode stem cell-niche interactions to treat muscle degeneration and aging. Grants: NIH K99/R00, R01, R21; Glenn Medical Research Foundation Labs/Teams: Cosgrove Lab (Cornell University) Future Work: Expanding applications of spatial transcriptomics and engineering regenerative therapies for muscle diseases
Dr. Rodolfo J. Flores serves as an Assistant Professor in the Department of Psychology within the College of Liberal Arts at the University of Texas at El Paso (UTEP). His primary research investigates neuromodulator function in the prefrontal cortex, with emphasis on acetylcholine and dynorphin systems during motivational conflict, stress responses, and addiction pathways. He employs advanced optogenetic and biosensor technologies to dissect neural circuitry underlying psychiatric conditions. Dr. Flores earned his Ph.D. in Social Cognitive and Neuroscience from UTEP in 2019, followed by postdoctoral training at the National Institute of Mental Health (NIMH). His work bridges molecular neuroscience with behavioral outcomes, focusing on how stress and substance exposure alter prefrontal cortical function. His research portfolio demonstrates consistent high-impact publication in top neuroscience journals including Nature Neuroscience , Neuron , and Psychoneuroendocrinology . Current work examines opioid neuropeptide dynamics, nicotine-alcohol interactions, and sex-specific hormonal influences on addiction behaviors. Methodologically, he specializes in genetically encoded biosensors and circuit-level manipulations to study threat processing and reward pathways. Dr. Flores teaches graduate and undergraduate courses including PSYC 4341 (Motivation & Emotion), thesis/dissertation supervision (PSYC 5395/6395), and research applications courses. His lab actively trains students through undergraduate research (RSRC 4033) and independent study opportunities (PSYC 4352).
